Elicera Therapeutics AB (ELIC) - Total Liabilities
Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has total liabilities worth Skr6.97 Million SEK (≈ $750.01K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Elicera Therapeutics AB - Total Liabilities Trend (2014–2024)
This chart illustrates how Elicera Therapeutics AB's total liabilities have evolved over time, based on quarterly financial data. See Elicera Therapeutics AB (ELIC) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Elicera Therapeutics AB Competitors by Total Liabilities
The table below lists competitors of Elicera Therapeutics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Mcnulty Co Ltd
KQ:222980
|
Korea | ₩46.00 Billion |
|
Weizmann Limited
NSE:WEIZMANIND
|
India | Rs286.18 Million |
|
In8bio Inc
NASDAQ:INAB
|
USA | $3.48 Million |
|
Inter-M Corporation
KQ:017250
|
Korea | ₩49.66 Billion |
|
Vitura Health Ltd
AU:VIT
|
Australia | AU$31.49 Million |
|
Southern Hemisphere Mining Ltd
AU:SUH
|
Australia | AU$574.02K |
|
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk PT
JK:JMAS
|
Indonesia | Rp249.32 Billion |
|
Jadi Imaging Holdings Bhd
KLSE:7223
|
Malaysia | RM1.59 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Elicera Therapeutics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ELIC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elicera Therapeutics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elicera Therapeutics AB (2014–2024)
The table below shows the annual total liabilities of Elicera Therapeutics AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.79 Million ≈ $730.97K |
-50.70% |
| 2023-12-31 | Skr13.78 Million ≈ $1.48 Million |
+2.00% |
| 2022-12-31 | Skr13.51 Million ≈ $1.45 Million |
+440.31% |
| 2021-12-31 | Skr2.50 Million ≈ $269.05K |
+6.22% |
| 2020-12-31 | Skr2.35 Million ≈ $253.30K |
+58742.88% |
| 2019-12-31 | Skr4.00K ≈ $430.46 |
0.00% |
| 2018-12-31 | Skr4.00K ≈ $430.46 |
0.00% |
| 2017-12-31 | Skr4.00K ≈ $430.46 |
-96.79% |
| 2016-12-31 | Skr124.60K ≈ $13.41K |
-66.03% |
| 2015-12-31 | Skr366.76K ≈ $39.47K |
-38.55% |
| 2014-12-31 | Skr596.87K ≈ $64.23K |
-- |
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more